1
|
Imakura Y, Mima S, Yamazaki N, Inomata A, Mochizuki S, Iwao T, Matsunaga T. Utility of human induced pluripotent stem cell-derived small intestinal epithelial cells for pharmacokinetic, toxicological, and immunological studies. Biochem Biophys Res Commun 2024; 692:149356. [PMID: 38071890 DOI: 10.1016/j.bbrc.2023.149356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2023] [Revised: 11/21/2023] [Accepted: 12/03/2023] [Indexed: 01/06/2024]
Abstract
The small intestine, which plays a crucial role in the absorption and metabolism of drugs and foods, serves as a target organ for drug-induced toxicity and immune interactions with functional foods and intestinal bacteria. Current alternative models of the human small intestine, such as Caco-2 cells and experimental animals, have limitations due to variations in the expression levels of metabolic enzymes, transporters, and receptors. This study presents investigations into the utility of human induced pluripotent stem cell-derived small intestinal epithelial cells (hiSIECs) for pharmacokinetic, toxicological, and immunological studies, respectively. While hiSIECs displayed small intestinal epithelial cell characteristics and barrier function, they demonstrated pharmacokinetic properties such as cytochrome P450 3A4/5 activity equivalent to human primary enterocytes and stable P-glycoprotein activity. These cells also demonstrated potential for assessing two forms of intestinal toxicity caused by anticancer drugs and gamma-secretase inhibitors, displaying immune responses mediated by toll-like and fatty acid receptors while serving as an inflammatory gut model through the addition of tumor necrosis factor alpha and interferon gamma. Overall, hiSIECs hold promise as an in vitro model for assessing pharmacokinetics, toxicity, and effects on the intestinal immunity of pharmaceuticals, functional foods, supplements, and intestinal bacteria.
Collapse
Affiliation(s)
- Yuki Imakura
- Bio Science & Engineering Laboratory, FUJIFILM Corporation, 577 Ushijima, Kaisei-machi, Ashigarakami-gun, Kanagawa, 258-8577, Japan; Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, 467-8603, Japan
| | - Shinji Mima
- Bio Science & Engineering Laboratory, FUJIFILM Corporation, 577 Ushijima, Kaisei-machi, Ashigarakami-gun, Kanagawa, 258-8577, Japan
| | - Nao Yamazaki
- Bio Science & Engineering Laboratory, FUJIFILM Corporation, 577 Ushijima, Kaisei-machi, Ashigarakami-gun, Kanagawa, 258-8577, Japan
| | - Akira Inomata
- Bio Science & Engineering Laboratory, FUJIFILM Corporation, 577 Ushijima, Kaisei-machi, Ashigarakami-gun, Kanagawa, 258-8577, Japan
| | - Seiichi Mochizuki
- Bio Science & Engineering Laboratory, FUJIFILM Corporation, 577 Ushijima, Kaisei-machi, Ashigarakami-gun, Kanagawa, 258-8577, Japan
| | - Takahiro Iwao
- Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, 467-8603, Japan.
| | - Tamihide Matsunaga
- Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya, 467-8603, Japan
| |
Collapse
|
2
|
Yamazaki N, Kiyohara Y, Sato M, Endo S, Song B, Tanaka Y, Kambe A, Sato Y, Uhara H. 407P A post-marketing surveillance of the real-world safety and effectiveness of avelumab in patients with curatively unresectable Merkel cell carcinoma in Japan. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
|
3
|
Dummer R, Pathan N, Deng S, Robert C, Arance Fernandez A, de Groot J, Garbe C, Gogas H, Gutzmer R, Krajsova I, Liszkay G, Loquai C, Mandala M, Schadendorf D, Yamazaki N, di Pietro A, Xie T, Ascierto P, Flaherty K. 786O Tumor biomarker analysis from COLUMBUS part 1: Encorafenib + binimetinib for BRAF V600E/K-mutant advanced or metastatic melanoma. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.912] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
4
|
Bai X, Gerstberger S, Park B, Jung S, Johnson R, Yamazaki N, Ogata D, Umeda Y, Li C, Si L, Flaherty K, Nakamura Y, Namikawa K, Long G, Menzies A, Johnson D, Sullivan R, Boland G, Guo J. 807P Adjuvant anti-PD-1 monotherapy benefit varies across different ethnicities and melanoma subtypes. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.933] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
5
|
Nakamura Y, Namikawa K, Yoshikawa S, Kiniwa Y, Maekawa T, Yamasaki O, Isei T, Matsushita S, Nomura M, Nakai Y, Fukushima S, Saito S, Takenouchi T, Tanaka R, Kato H, Otsuka A, Matsuya T, Baba N, Nagase K, Inozume T, Fujimoto N, Kuwatsuka Y, Onishi M, Kaneko T, Onuma T, Umeda Y, Ogata D, Takahashi A, Otsuka M, Teramoto Y, Yamazaki N. Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study). ESMO Open 2021; 6:100325. [PMID: 34839104 PMCID: PMC8633880 DOI: 10.1016/j.esmoop.2021.100325] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2021] [Accepted: 10/29/2021] [Indexed: 01/14/2023] Open
Abstract
Background Anti-programmed cell death protein 1 (PD-1) antibody monotherapy (PD1) has led to favorable responses in advanced non-acral cutaneous melanoma among Caucasian populations; however, recent studies suggest that this therapy has limited efficacy in mucosal melanoma (MCM). Thus, advanced MCM patients are candidates for PD1 plus anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) combination therapy (PD1 + CTLA4). Data on the efficacy of immunotherapy in MCM, however, are limited. We aimed to compare the efficacies of PD1 and PD1 + CTLA4 in Japanese advanced MCM patients. Patients and methods We retrospectively assessed advanced MCM patients treated with PD1 or PD1 + CTLA4 at 24 Japanese institutions. Patient baseline characteristics, clinical responses (RECIST), progression-free survival (PFS), and overall survival (OS) were estimated using Kaplan–Meier analysis, and toxicity was assessed to estimate the efficacy and safety of PD1 and PD1 + CTLA4. Results Altogether, 329 patients with advanced MCM were included in this study. PD1 and PD1 + CTLA4 were used in 263 and 66 patients, respectively. Baseline characteristics were similar between both treatment groups, except for age (median age 71 versus 65 years; P < 0.001). No significant differences were observed between the PD1 and PD1 + CTLA4 groups with respect to objective response rate (26% versus 29%; P = 0.26) or PFS and OS (median PFS 5.9 months versus 6.8 months; P = 0.55, median OS 20.4 months versus 20.1 months; P = 0.55). Cox multivariate survival analysis revealed that PD1 + CTLA4 did not prolong PFS and OS (PFS: hazard ratio 0.83, 95% confidence interval 0.58-1.19, P = 0.30; OS: HR 0.89, 95% confidence interval 0.57-1.38, P = 0.59). The rate of ≥grade 3 immune-related adverse events was higher in the PD1 + CTLA4 group than in the PD1 group (53% versus 17%; P < 0.001). Conclusions First-line PD1 + CTLA4 demonstrated comparable clinical efficacy to PD1 in Japanese MCM patients, but with a higher rate of immune-related adverse events. Anti-PD-1 plus anti-CTLA-4 antibody therapy (PD1 + CTLA4) is an option for patients with advanced mucosal melanoma (MCM). Data on the efficacy of PD1 + CTLA4 compared with PD-1 monotherapy (PD1) for MCM, however, are limited. We retrospectively analyzed data from 329 Japanese patients with advanced MCM treated with PD1 or PD1 + CTLA4. No significant differences in objective response rate, progression-free survival, or overall survival were observed. Immune-related adverse events resulting in treatment cessation were higher in the PD1 + CTLA4 group.
Collapse
Affiliation(s)
- Y Nakamura
- Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, Japan.
| | - K Namikawa
- Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - S Yoshikawa
- Department of Dermatology, Shizuoka Cancer Center, Shizuoka, Japan
| | - Y Kiniwa
- Department of Dermatology, Shinshu University, Matsumoto, Japan
| | - T Maekawa
- Department of Dermatology, Jichi Medical University, Tochigi, Japan
| | - O Yamasaki
- Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - T Isei
- Department of Dermatologic Oncology, Osaka International Cancer Institute, Osaka, Japan
| | - S Matsushita
- Department of Dermato-Oncology/Dermatology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan
| | - M Nomura
- Department of Clinical Oncology, Kyoto University, Kyoto, Japan
| | - Y Nakai
- Department of Dermatology, Mie University, Tsu, Japan
| | - S Fukushima
- Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
| | - S Saito
- Department of Dermatology, Gunma University, Maebashi, Japan
| | - T Takenouchi
- Department of Dermatology, Niigata Cancer Center, Niigata, Japan
| | - R Tanaka
- Department of Dermatology, Kawasaki Medical School, Kurashiki, Japan
| | - H Kato
- Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
| | - A Otsuka
- Department of Dermatology, Kyoto University, Kyoto, Japan
| | - T Matsuya
- Department of Dermatology, Asahikawa Medical University, Asahikawa, Japan
| | - N Baba
- Department of Dermatology, Fukui University, Fukui, Japan
| | - K Nagase
- Division of Dermatology, Department of Internal Medicine, Saga University, Saga, Japan
| | - T Inozume
- Department of Dermatology, Chiba University, Chiba, Japan
| | - N Fujimoto
- Department of Dermatology, Shiga University of Medical Science, Otsu, Japan
| | - Y Kuwatsuka
- Department of Dermatology, Nagasaki University, Nagasaki, Japan
| | - M Onishi
- Department of Dermatology, Iwate Medical University, Morioka, Japan
| | - T Kaneko
- Department of Dermatology, Juntendo University Urayasu Hospital, Urayasu, Japan
| | - T Onuma
- Department of Dermatology, Yamanashi University, Kofu, Japan
| | - Y Umeda
- Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, Japan; Department of Dermatology, Kawasaki Medical School, Kurashiki, Japan
| | - D Ogata
- Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - A Takahashi
- Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - M Otsuka
- Department of Dermatology, Shizuoka Cancer Center, Shizuoka, Japan
| | - Y Teramoto
- Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, Japan
| | - N Yamazaki
- Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan
| |
Collapse
|
6
|
Dummer R, Flaherty K, Robert C, Arance A, de Groot J, Garbe C, Gogas H, Gutzmer R, Krajsová I, Liszkay G, Loquai C, Mandala M, Schadendorf D, Yamazaki N, Zohren F, Edwards M, Ascierto P. 1041MO 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1426] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
7
|
Shinha K, Nihei W, Nakamura H, Goto T, Kawanishi T, Ishida N, Yamazaki N, Imakura Y, Mima S, Inamura K, Arakawa H, Nishikawa M, Kato Y, Sakai Y, Kimura H. A Kinetic Pump Integrated Microfluidic Plate (KIM-Plate) with High Usability for Cell Culture-Based Multiorgan Microphysiological Systems. Micromachines (Basel) 2021; 12:1007. [PMID: 34577652 PMCID: PMC8471412 DOI: 10.3390/mi12091007] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/21/2021] [Revised: 08/18/2021] [Accepted: 08/19/2021] [Indexed: 11/18/2022]
Abstract
Microphysiological systems (MPSs), including organ-on-a-chip (OoC), have attracted attention as a novel method for estimating the effects and side effects of drugs in drug discovery. To reproduce the dynamic in vivo environment, previous MPSs were connected to pump systems to perfuse culture medium. Therefore, most MPSs are not user-friendly and have poor throughput. We aimed to develop a kinetic pump integrated microfluidic plate (KIM-Plate) by applying the stirrer-based micropump to an open access culture plate to improve the usability of MPSs. The KIM-Plate integrates six multiorgan MPS (MO-MPS) units and meets the ANSI/SBS microplate standards. We evaluated the perfusion function of the kinetic pump and found that the KIM-Plate had sufficient agitation effect. Coculture experiments with PXB cells and hiPS intestinal cells showed that the TEER of hiPS intestinal cells and gene expression levels related to the metabolism of PXB cells were increased. Hence, the KIM-Plate is an innovative tool for the easy coculture of highly conditioned cells that is expected to facilitate cell-based assays in the fields of drug discovery and biology because of its usability and high throughput nature.
Collapse
Affiliation(s)
- Kenta Shinha
- Department of Mechanical Engineering, School of Engineering, Tokai University, 4-1-1 Kitakaname, Hiratsuka 259-1292, Japan; (K.S.); (W.N.); (H.N.); (T.G.)
| | - Wataru Nihei
- Department of Mechanical Engineering, School of Engineering, Tokai University, 4-1-1 Kitakaname, Hiratsuka 259-1292, Japan; (K.S.); (W.N.); (H.N.); (T.G.)
- Micro/Nano Technology Center, Tokai University, 4-1-1 Kitakaname, Hiratsuka 259-1292, Japan
| | - Hiroko Nakamura
- Department of Mechanical Engineering, School of Engineering, Tokai University, 4-1-1 Kitakaname, Hiratsuka 259-1292, Japan; (K.S.); (W.N.); (H.N.); (T.G.)
| | - Tomomi Goto
- Department of Mechanical Engineering, School of Engineering, Tokai University, 4-1-1 Kitakaname, Hiratsuka 259-1292, Japan; (K.S.); (W.N.); (H.N.); (T.G.)
| | - Takumi Kawanishi
- Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa 920-1192, Japan; (T.K.); (N.I.); (H.A.); (Y.K.)
| | - Naoki Ishida
- Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa 920-1192, Japan; (T.K.); (N.I.); (H.A.); (Y.K.)
| | - Nao Yamazaki
- Bio Science & Engineering Laboratory, FUJIFILM Corporation, 577 Ushijima, Kaisei-machi 258-8577, Japan; (N.Y.); (Y.I.); (S.M.)
| | - Yuki Imakura
- Bio Science & Engineering Laboratory, FUJIFILM Corporation, 577 Ushijima, Kaisei-machi 258-8577, Japan; (N.Y.); (Y.I.); (S.M.)
| | - Shinji Mima
- Bio Science & Engineering Laboratory, FUJIFILM Corporation, 577 Ushijima, Kaisei-machi 258-8577, Japan; (N.Y.); (Y.I.); (S.M.)
| | - Kosuke Inamura
- Department of Chemical System Engineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Tokyo 113-8654, Japan; (K.I.); (M.N.); (Y.S.)
| | - Hiroshi Arakawa
- Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa 920-1192, Japan; (T.K.); (N.I.); (H.A.); (Y.K.)
| | - Masaki Nishikawa
- Department of Chemical System Engineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Tokyo 113-8654, Japan; (K.I.); (M.N.); (Y.S.)
| | - Yukio Kato
- Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa 920-1192, Japan; (T.K.); (N.I.); (H.A.); (Y.K.)
| | - Yasuyuki Sakai
- Department of Chemical System Engineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Tokyo 113-8654, Japan; (K.I.); (M.N.); (Y.S.)
| | - Hiroshi Kimura
- Department of Mechanical Engineering, School of Engineering, Tokai University, 4-1-1 Kitakaname, Hiratsuka 259-1292, Japan; (K.S.); (W.N.); (H.N.); (T.G.)
- Micro/Nano Technology Center, Tokai University, 4-1-1 Kitakaname, Hiratsuka 259-1292, Japan
| |
Collapse
|
8
|
Nakamura Y, Namikawa K, Yoshino K, Yoshikawa S, Uchi H, Goto K, Nakamura Y, Fukushima S, Kiniwa Y, Takenouchi T, Uhara H, Kawai T, Hatta N, Funakoshi T, Teramoto Y, Otsuka A, Doi H, Ogata D, Matsushita S, Isei T, Hayashi T, Shibayama Y, Yamazaki N. Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients. Ann Oncol 2020; 31:1198-1206. [PMID: 32522691 DOI: 10.1016/j.annonc.2020.05.031] [Citation(s) in RCA: 84] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2020] [Revised: 05/04/2020] [Accepted: 05/28/2020] [Indexed: 01/07/2023] Open
Abstract
BACKGROUND Acral melanoma (AM) is an epidemiologically and molecularly distinct entity that is underrepresented in clinical trials on immunotherapy in melanoma. We aimed to analyze the efficacy of anti-programmed cell death 1 (anti-PD-1) antibodies in advanced AM. PATIENTS AND METHODS We retrospectively evaluated unresectable stage III or stage IV AM patients treated with an anti-PD-1 antibody in any line at 21 Japanese institutions between 2014 and 2018. The clinicobiologic characteristics, objective response rate (ORR, RECIST), survival estimated using Kaplan-Meier analysis, and toxicity (Common Terminology Criteria for Adverse Events 4.0.) were analyzed to estimate the efficacy of the anti-PD-1 antibodies. RESULTS In total, 193 patients (nail apparatus, 70; palm and sole, 123) were included in the study. Anti-PD-1 antibody was used as first-line therapy in 143 patients (74.1%). Baseline lactate dehydrogenase (LDH) was within the normal concentration in 102 patients (52.8%). The ORR of all patients was 16.6% (complete response, 3.1%; partial response, 13.5%), and the median overall survival (OS) was 18.1 months. Normal LDH concentrations showed a significantly stronger association with better OS than abnormal concentrations (median OS 24.9 versus 10.7 months; P < 0.001). Although baseline characteristics were similar between the nail apparatus and the palm and sole groups, ORR was significantly lower in the nail apparatus group [6/70 patients (8.6%) versus 26/123 patients (21.1%); P = 0.026]. Moreover, the median OS in this group was significantly poorer (12.8 versus 22.3 months; P = 0.03). CONCLUSIONS Anti-PD-1 antibodies have limited efficacy in AM patients. Notably, patients with nail apparatus melanoma had poorer response and survival, making nail apparatus melanoma a strong candidate for further research on the efficacy of novel combination therapies with immune checkpoint inhibitors.
Collapse
Affiliation(s)
- Y Nakamura
- Department of Skin Oncology/Dermatology, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Saitama, Japan.
| | - K Namikawa
- Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - K Yoshino
- Department of Dermatologic Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
| | - S Yoshikawa
- Department of Dermatology, Shizuoka Cancer Center, Shizuoka, Japan
| | - H Uchi
- Department of Dermatology, Kyushu University, Fukuoka, Japan
| | - K Goto
- Department of Dermatology, Nagoya University, Nagoya, Japan
| | - Y Nakamura
- Department of Dermatology, University of Tsukuba, Tsukuba, Japan
| | - S Fukushima
- Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
| | - Y Kiniwa
- Department of Dermatology, Shinshu University, Matsumoto, Japan
| | - T Takenouchi
- Department of Dermatology, Niigata Cancer Center, Niigata, Japan
| | - H Uhara
- Department of Dermatology, Sapporo Medical University, Sapporo, Japan
| | - T Kawai
- Department of Dermatology, University of Tokyo, Tokyo, Japan
| | - N Hatta
- Department of Dermatology, Toyama Prefectural Central Hospital, Toyama, Japan
| | - T Funakoshi
- Department of Dermatology, Keio University, Tokyo, Japan
| | - Y Teramoto
- Department of Skin Oncology/Dermatology, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Saitama, Japan
| | - A Otsuka
- Department of Dermatology, Kyoto University, Kyoto, Japan
| | - H Doi
- Department of Dermatology, Asahikawa Medical University, Asahikawa, Japan
| | - D Ogata
- Department of Dermatology, Saitama Medical University, Saitama, Japan
| | - S Matsushita
- Department of Dermato-Oncology/Dermatology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan
| | - T Isei
- Department of Dermatological Oncology, Osaka International Cancer Institute, Osaka, Japan
| | - T Hayashi
- Plastic and Reconstructive Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Y Shibayama
- Department of Dermatology, Fukuoka University, Fukuoka, Japan
| | - N Yamazaki
- Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan
| |
Collapse
|
9
|
Kaku S, Horinouchi H, Watanabe H, Tamura K, Okusaka T, Boku N, Yamazaki N, Ohe Y, Kusumoto M. Pneumonitis induced antineoplastic agents: Mortality and risk factors in 129 consecutive cases. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz434.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Yamazaki N, Takahashi A, Namikawa K, Takenouchi T, Nakamura Y, Kitano S, Fujita T, Kubota K, Yamanaka T, Kawakami Y. Response of nivolumab monotherapy in 124 Japanese patients with advanced melanoma: Interim analysis of prospective observational study (CREATIVE study). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz429.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
11
|
Yokota K, Isei T, Uhara H, Fujisawa Y, Takenouchi T, Kiyohara Y, Uchi H, Saruta H, Ihn H, Inozume T, Watanabe D, Takahashi A, Fukushima S, Tanaka M, Yamazaki N. Final results from phase II of combination with canerpaturev (formerly HF10), an oncolytic viral immunotherapy, and ipilimumab in unresectable or metastatic melanoma in second-or later line treatment. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz255.053] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
12
|
Yamazaki N, Kikuchi K, Nozawa K, Fukuda H, Shibata T, Hamaguchi T, Takashima A, Shoji H, Boku N, Takatsuka S, Takenouchi T, Nishina T, Hino K, Yoshikawa S, Yamazaki K, Takahashi M, Hasegawa A, Bando H, Masuishi T, Kiyohara Y. Primary analysis results of randomized controlled trial evaluating reactive topical corticosteroid strategies for the facial acneiform rash by EGFR inhibitors (EGFRIs) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC): FAEISS study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
13
|
Robert C, Dummer R, Ascierto P, Gogas H, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot J, Yamazaki N, Loquai C, Moutouh-de Parseval L, Pickard M, Sandor V, Flaherty K. Données de survie globale de l’étude COLUMBUS, étude de phase III avec encorafénib (ENCO) plus binimétinib (BINI) versus vémurafénib (VEM) ou encorafénib (ENCO) dans le mélanome métastatique BRAF muté. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
14
|
jinnai S, Namikawa K, Nakano E, Takahashi A, Yamazaki N. Location of malignant melanoma in distal extremity draining to popliteal or epitrochlear sentinel lymph nodes. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy439.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Yamazaki N, Koga H, Kojima T, Tsutsumida A, Namikawa K, Yi M, Mera K, Pickett-Gies C. Early safety from a phase I, multicenter, open-label, dose de-escalation study of talimogene laherparepvec (T-VEC) in Japanese patients (pts) with unresectable stage IIIB-IV melanoma (MEL). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy439.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
16
|
Namikawa K, Mori T, Muto Y, jinnai S, Kage Y, Nakano E, Takahashi A, Yamazaki N. PD-L1 expression and clinical outcome after nivolumab monotherapy in various subtypes of melanoma: A single-institutional retrospective study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy439.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Nakamura Y, Takahashi A, Namikawa K, Takenouchi T, Kitano S, Fujita T, Kubota K, Yamanaka T, Kawakami Y, Yamazaki N. Interim analysis of prospective observational study on the efficacy of nivolumab for Japanese advanced melanoma patients (CREATIVE study). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy439.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
18
|
Isei T, Yokota K, Uhara H, Fujisawa Y, Takenouchi T, Kiyohara Y, Uchi H, Saruta H, Ihn H, Inozume T, Watanabe D, Takahashi A, Fukushima S, Tanaka M, Yamazaki N. Topline results from phase II of combination treatment with canerpaturev (HF10), an oncolytic viral immunotherapy, and ipilimumab in patients with unresectable or metastatic melanoma after anti-PD-1 therapy. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy289.023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Okamoto K, Yamazaki N, Kobe A, Kagechika K. Factors to estimate swallowing function in patients with acute stroke. Ann Phys Rehabil Med 2018. [DOI: 10.1016/j.rehab.2018.05.447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
20
|
Namikawa K, Takahashi A, Tsutsumida A, Mori T, Motoi N, Jinnai S, Kage Y, Muto Y, Nakano E, Yamazaki N. Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: A single-institutional retrospective study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx667.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Yamazaki N, Takahashi A, Tsutsumida A, Tanaka M, Namikawa K. Final results of phase I trial of HF10, oncolytic virus immunotherapy, in Japanese patients with refractory superficial cancers. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx667.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
22
|
Kiyohara Y, Takenouchi T, Uhara H, Koga H, Uchi H, Yamazaki N. Phase 2 study to evaluate efficacy and safety of combination therapy with nivolumab (NIVO) and ipilimumab(IPI) in patients with previously untreated melanoma. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx667.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
Nojima K, Namiki T, Funazumi M, Ishikawa M, Kaneko Y, Tanemura A, Katamaya I, Mori T, Yamazaki N, Yokozeki H, Hearing V. 606 NUAK2 over expressed and DNA copy number increased in acral melanoma: Its significance on the survival of patients. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.07.803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
24
|
Hasegawa A, Maehara M, Yamazaki N, Shigehara Y, Abe R. 487 Phosphorylated MLKL and cleaved caspase8 are useful for early diagnosis of Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.07.683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
25
|
Arance A, Dummer R, Ascierto P, Gogas H, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsová I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot J, Yamazaki N, Loquai C, de Parseval L, Pickard M, Sandor V, Robert C, Flaherty K. Hospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx377.030] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
26
|
Dummer R, Ascierto P, Gogas H, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsová I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot J, Yamazaki N, Loquai C, de Parseval L, Pickard M, Sandor V, Robert C, Flaherty K. Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx377.002] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Gogas H, Dummer R, Ascierto P, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsová I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot J, Yamazaki N, Loquai C, de Parseval L, Pickard M, Sandor V, Robert C, Flaherty K. Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx377.031] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Omata W, Tsutsumida A, Namikawa K, Takahashi A, Oashi K, Yamazaki N. Sequential Combination Chemotherapy of Dacarbazine (DTIC) with Carboplatin and Paclitaxel for Patients with Metastatic Mucosal Melanoma of Nasal Cavity and Paranasal Sinuses. Clin Med Insights Case Rep 2017; 10:1-5. [PMID: 28096700 PMCID: PMC5224238 DOI: 10.4137/ccrep.s39851] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2016] [Revised: 11/06/2016] [Accepted: 11/13/2016] [Indexed: 12/16/2022]
Abstract
By the recent introduction of molecular targeting drugs against BRAF mutation and immune checkpoint inhibitors, the prognosis of patients with melanoma in advanced stage is now improving, but still in the minority. Mucosal melanoma lacks the BRAF mutations, and hence conventional chemotherapeutic regimens must be improved. We have conventionally used dacarbazine (DTIC) for patients with metastatic mucosal melanoma. However, the efficacy of DTIC in patients with metastatic mucosal melanoma has been limited. Therefore, we explored other possibilities to improve the prognosis of patients suffering from metastatic mucosal melanoma. In this communication, we present a retrospective analysis of the sequential combination chemotherapy of DTIC with carboplatin and paclitaxel (CP) for metastatic mucosal melanoma of nasal cavity and paranasal sinuses. The objective response rate of seven patients is 14.3% by RECIST 1.1 and the overall survival (OS) is 12.5 months. These data indicate that the sequential combination chemotherapy of DTIC with CP could be an option for patients with metastatic mucosal melanoma of nasal cavity and paranasal sinuses who are currently ending into dismal prognosis.
Collapse
Affiliation(s)
- W Omata
- Department of Dermatologic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
| | - A Tsutsumida
- Department of Dermatologic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
| | - K Namikawa
- Department of Dermatologic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
| | - A Takahashi
- Department of Dermatologic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
| | - K Oashi
- Department of Dermatologic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
| | - N Yamazaki
- Department of Dermatologic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
| |
Collapse
|
29
|
Sakaguchi H, Ishida H, Nitanda H, Yamazaki N, Kaneko K, Kobayashi K. Pharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural effusion. Lung Cancer 2016; 104:70-74. [PMID: 28213004 DOI: 10.1016/j.lungcan.2016.12.015] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2016] [Revised: 12/10/2016] [Accepted: 12/20/2016] [Indexed: 10/20/2022]
Abstract
OBJECTIVES Malignant pleural effusion (MPE) has a poor prognosis. Most patients are treated with tube thoracostomy and sclerotherapy, although its success rate is around 64%. We have investigated intrapleural perfusion with hyperthermic chemotherapy (IPHC) using cisplatin in a study with a pharmacokinetic evaluation. METHODS Patients with MPE, performance status of 0-1, possibility of good lung expansion and Cr<1.2mg/dL were treated with IPHC. The circuit was filled with 2000mL of normal saline containing cisplatin at a dose of 80mg/m2. Under video-assisted thoracoscopic surgery, the thoracic cavity was filled and perfused at a speed of approximately 1L/min at a temperature of 43°C for 1h. Perfusion solution and plasma samples were periodically collected, and concentrations of protein-unbound (free) platinum, which was the active derivative of cisplatin, and total platinum were determined by flameless atomic absorption spectrometry. RESULTS Twenty patients with MPE (8 lung cancers, 7 mesotheliomas, and 5 others) were enrolled in this study. Rate of free platinum concentration relative to total platinum concentration in perfusion solution after 1hr IPHC at 43°C was 61.1±12.9%. Area under curve (AUC) of free platinum in the pleural space was calculated to be 26.3μg/mLxh, resulting in complete control of pleural effusion for 3 months after IHPC in all cases (95% confidence interval: 83-100%). While, absorption rate of total platinum from the pleural space was 33.8±17.0% (27.4±13.6mg/m2), and the maximum concentration of total platinum in serum was low, 0.66±0.31μg/mL, resulting in controllable side effects; grade 1 renal toxicity: 6 patients, grade 1 emesis: 7 patients. CONCLUSIONS IPHC with cisplatin showed favorable pharmacokinetic profiles for an optional treatment to control malignant pleural effusion.
Collapse
Affiliation(s)
- Hirozo Sakaguchi
- Department of General Thoracic Surgery, Saitama Medical University International Medical Center, Saitama, Japan
| | - H Ishida
- Department of General Thoracic Surgery, Saitama Medical University International Medical Center, Saitama, Japan
| | - H Nitanda
- Department of General Thoracic Surgery, Saitama Medical University International Medical Center, Saitama, Japan
| | - N Yamazaki
- Department of General Thoracic Surgery, Saitama Medical University International Medical Center, Saitama, Japan
| | - K Kaneko
- Department of General Thoracic Surgery, Saitama Medical University International Medical Center, Saitama, Japan
| | - Kunihiko Kobayashi
- Department of General Thoracic Surgery, Saitama Medical University International Medical Center, Saitama, Japan.
| |
Collapse
|
30
|
Yamazaki N, Uhara H, Kiyohara Y. 406P Phase 2 study of nivolumab (NIVO) in Japanese patients with previously untreated advanced melanoma: long-term efficacy and safety. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw589.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Tsutsumida A, Yamazaki N, Takahashi A, Namikawa K. 408P Ipilimumab after nivolumab therapy for melanoma patients in Asia. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw589.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
32
|
Tsutsumida A, Yamazaki N, Takahashi A, Namikawa K. 408P Ipilimumab after nivolumab therapy for melanoma patients in Asia. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00566-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
33
|
Maruki Y, Kondo S, Oshiro Y, Yutaka F, Namikawa K, Takahashi A, Tsutsumida A, Yamazaki N. 402P Detailed clinical course of immune-related hepatotoxicity in advanced melanoma patients using immune checkpoint inhibitors. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw588.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Yamazaki N, Uhara H, Kiyohara Y. 406P Phase 2 study of nivolumab (NIVO) in Japanese patients with previously untreated advanced melanoma: long-term efficacy and safety. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00564-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
35
|
Nakamura Y, Kitano S, Takahashi A, Tsutsumida A, Namikawa K, Muto I, Ueno M, Muto Y, Yamazaki N. Pretreatment prognostic factors and early markers for outcome in advanced melanoma treated with nivolumab. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw379.24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
36
|
Takahashi A, Tsutsumida A, Namikawa K, Nakamura Y, Muto I, Yamazaki N. The efficacy of nivolumab for unresectable metastatic mucosal melanoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw379.14] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Shiono S, Okumura T, Boku N, Hishida T, Ohde Y, Sakao Y, Yoshiya K, Higashiyama M, Kameyama K, Adachi H, Shiomi K, Kanzaki M, Yoshimura M, Matsuura M, Hata Y, Chen F, Yoshida K, Sasaki H, Horio H, Takenoyama M, Yamashita M, Hashimoto T, Fujita A, Okumura M, Funai K, Asano H, Suzuki M, Shiraishi Y, Nakayama M, Yamada S, Hoshi E, Yamazaki N, Matsuo T, Miyazawa H, Sato Y, Takao M, Nakamura H, Nakayama H, Shimizu K, Watanabe T, Suzuki H, Kataoka M, Tsunezuka Y, Akamine S, Kadokura M, Hyodo I, Nakata M, Mori K, Kondo H. O-089OUTCOMES OF SEGMENTECTOMY AND WEDGE RESECTION FOR PULMONARY COLORECTAL CANCER METASTASES. Interact Cardiovasc Thorac Surg 2016. [DOI: 10.1093/icvts/ivw260.88] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
38
|
Namiki T, Funazaumi M, Nojima K, Ishikawa M, Tanemura A, Katamaya I, Mori T, Yamazaki N, Yokozeki H, Hearing V. 464 Overexpression of NUAK2 has a significant impact on the survival of acral melanoma patients. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.06.486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
39
|
Tsutsumida A, Yamazaki N, Takahashi A, Namikawa K, Fujiwara Y, Kondo S, Yoshikawa S, Yoshino Y, Suzuki A, Mukaiyama A, Nishimura Y, Kiyohara Y. 346PD Evaluation of safety, tolerability, pharmacokinetics (PK) and efficacy of dabrafenib and trametinib combination (Dab + Tra) therapy in Japanese patients (pts) with BRAF V600 mutation-positive advanced cutaneous melanoma: a phase (Ph) I/II study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv528.03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Yamazaki N, Uhara H, Fukushima S, Uchi H, Shibagaki N, Kiyohara Y, Tsutsumida A, Namikawa K, Okuyama R, Otsuka Y, Tokudome T. Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma. Cancer Chemother Pharmacol 2015; 76:969-75. [PMID: 26407818 PMCID: PMC4612320 DOI: 10.1007/s00280-015-2870-0] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2015] [Accepted: 09/06/2015] [Indexed: 11/24/2022]
Abstract
PURPOSE Ipilimumab (IPI), a monoclonal antibody against immune-checkpoint receptor cytotoxic T lymphocyte antigen-4, is designed to enhance antitumor T cell function. IPI 10 mg/kg plus dacarbazine (DTIC) significantly improved overall survival in a phase 3 study involving predominantly Caucasian patients, with an adverse event (AE) profile similar to that of IPI monotherapy. We conducted a single-arm, phase 2 study to evaluate the safety and efficacy of IPI plus DTIC in Japanese patients. METHODS Previously untreated patients with unresectable stage III or IV melanoma received IPI 10 mg/kg plus DTIC 850 mg/m(2) every 3 weeks for four doses (q3w × 4), followed by DTIC q3w × 4 and then IPI every 12 weeks until disease progression or intolerable toxicity. RESULTS All 15 treated patients reported drug-related AEs, the most common of which were increases in alanine aminotransferase (n = 12, 80 %) and aspartate aminotransferase (n = 11, 73 %). Treatment-related serious AEs were reported in 11 (73 %) patients. Nine patients (60 %) discontinued treatment due to drug-related toxicities. Immune-related AEs (irAEs) were reported in 14 patients (93 %). The most frequent irAEs were liver (n = 12, 80 %) and skin (n = 10, 67 %) toxicities. Five deaths were reported; all were caused by progressive disease. Efficacy evaluation showed one complete response, one partial response and four patients with stable disease. Best overall response rate was 13 % (2/15), and the disease control rate was 40 % (6/15). The study was terminated early due to frequent, high-grade liver toxicities. CONCLUSIONS IPI 10 mg/kg plus DTIC 850 mg/m(2) was not considered tolerable in the Japanese patient population. ClinicalTrials.gov identifier: NCT01681212.
Collapse
Affiliation(s)
- N Yamazaki
- Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - H Uhara
- Department of Dermatology, Shinshu University School of Medicine, Matsumoto, Japan
| | - S Fukushima
- Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
| | - H Uchi
- Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - N Shibagaki
- Department of Dermatology, Yamanashi University Hospital, Yamanashi, Japan
| | - Y Kiyohara
- Dermatology Division, Shizuoka Cancer Center, Shizuoka, Japan
| | - A Tsutsumida
- Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - K Namikawa
- Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - R Okuyama
- Department of Dermatology, Shinshu University School of Medicine, Matsumoto, Japan
| | - Y Otsuka
- Research and Development, Bristol-Myers K.K., 6-5-1, Nishishinjuku, Shinjuku-ku, Tokyo, 163-1328, Japan
| | - T Tokudome
- Research and Development, Bristol-Myers K.K., 6-5-1, Nishishinjuku, Shinjuku-ku, Tokyo, 163-1328, Japan.
| |
Collapse
|
41
|
Nakamura Y, Namikawa K, Omata W, Takahashi A, Tsutsumida A, Yamazaki N. 3319 Outcomes of local treatment for malignant melanoma brain metastases: A single institution retrospective study. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31837-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
42
|
Yokota K, Takenouchi T, Fujimoto M, Ihn H, Uchi H, Inozume T, Kiyohara Y, Uhara H, Nakagawa K, Furukawa H, Wada H, Noguchi K, Shimamoto T, Yamazaki N. 3325 Safety and efficacy of Pembrolizumab (MK-3475) for Japanese patients (pts) with advanced melanoma: Preliminary results from KEYNOTE-041 Phase 1b study. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31843-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
43
|
Kobe A, Ikeda N, Yamazaki N, Yamamoto C, Funami Y, Kagechika K, Maeno T, Tiharu I. Falls incidents between a rehabilitation department and entire hospital: five-year comparative study. Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.3646] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
44
|
Yamazaki N, Wada N, Yamauchi C, Yoneyama K. High expression of post-treatment Ki-67 status is a risk factor for locoregional recurrence following breast-conserving surgery after neoadjuvant chemotherapy. Eur J Surg Oncol 2015; 41:617-24. [PMID: 25771264 DOI: 10.1016/j.ejso.2015.01.036] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2014] [Revised: 01/23/2015] [Accepted: 01/28/2015] [Indexed: 12/16/2022] Open
Abstract
INTRODUCTION During the past decade, neoadjuvant chemotherapy (NAC) has been increasingly used in patients to reduce large tumors to a size eligible for breast-conserving therapy (BCT). However, the association between NAC and Ki-67 has not yet been fully elucidated. The aim of this study was to evaluate the prognostic significance of Ki-67, specifically after NAC followed by BCT, particularly in terms of locoregional recurrence (LRR). METHODS A total 217 patients who received BCT after NAC were retrospectively analyzed. In these patients, immunohistochemistry analyses defined four tumor subtypes, Luminal A, Luminal B, Triple negative, and HER2 type. Ki-67 was examined by immunohistochemistry in both pretreatment core needle samples and post-treatment surgical excision specimens. High Ki-67 expression was defined as >20%. The prognostic factors LRR, locoregional relapse-free survival (LRRFS), and overall survival (OS) were analyzed. RESULTS In total, LRR developed in 14 patients, and the 5 year-LRRFS was 94.2%. Post-treatment high Ki-67 expression, triple negative, the presence of lymphovascular invasion, and histological grade 3 were significantly high in LRR for prognostic factors (P < 0.05). There were significant differences in Kaplan-Meier method for LRRFS curves according to these three factors for patients receiving BCT following NAC (P < 0.05). There was a significant difference in the 5 year-OS for patients with and without LRR (41.7% vs. 93.9%, P < 0.001). CONCLUSION Post-treatment high Ki-67 expression could be one of the important prognostic factors of LRR, and require careful follow-up on LRR at the time of surveillance.
Collapse
Affiliation(s)
- N Yamazaki
- Department of Breast Surgery, National Cancer Center Hospital East, Kashiwa, Japan
| | - N Wada
- Department of Breast Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
| | - C Yamauchi
- Department of Breast Surgery, National Cancer Center Hospital East, Kashiwa, Japan
| | - K Yoneyama
- Department of Breast Surgery, National Cancer Center Hospital East, Kashiwa, Japan
| |
Collapse
|
45
|
Yamazaki N, Kiyohara Y, Yoshikawa S, Yamamoto N, Tsutsumida A, Nokihara H, Namikawa K, Fujiwara Y, Suzuki A, Mukaiyama A, Tamura T. Evaluation of Safety, Tolerability, Pharmacokinetics and Efficacy of Dabrafenib, a Braf Inhibitor, in Japanese Patients with Braf V600 Mutation-Positive Advanced Solid Tumors: a Phase I Study. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu344.23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Kiyohara Y, Tahara H, Uhara H, Moroi Y, Yamazaki N. Long-Term Survival of Patients with Advanced Melanoma in Phase 2 Study of Nivolumab (Anti-Pd-1; Ono-4538/Bms-936558). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu344.12] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
47
|
Oashi K, Tsutsumida A, Namikawa K, Tanaka R, Omata W, Yamamoto Y, Yamazaki N. Combination chemotherapy for metastatic extramammary Paget disease. Br J Dermatol 2014; 170:1354-7. [DOI: 10.1111/bjd.12788] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/07/2013] [Indexed: 10/25/2022]
Affiliation(s)
- K. Oashi
- Department of Dermatologic Oncology; National Cancer Center Hospital; 5-1-1 Tsukiji, Chuo-ku Tokyo 104-0045 Japan
- Department of Plastic and Reconstructive Surgery; Graduate School of Medicine; University of Hokkaido at Sapporo, Kita-15 Nishi-7, Kita-Ku, Sapporo Hokkaido, 060-8638 Japan
| | - A. Tsutsumida
- Department of Dermatologic Oncology; National Cancer Center Hospital; 5-1-1 Tsukiji, Chuo-ku Tokyo 104-0045 Japan
| | - K. Namikawa
- Department of Dermatologic Oncology; National Cancer Center Hospital; 5-1-1 Tsukiji, Chuo-ku Tokyo 104-0045 Japan
| | - R. Tanaka
- Department of Dermatologic Oncology; National Cancer Center Hospital; 5-1-1 Tsukiji, Chuo-ku Tokyo 104-0045 Japan
| | - W. Omata
- Department of Dermatologic Oncology; National Cancer Center Hospital; 5-1-1 Tsukiji, Chuo-ku Tokyo 104-0045 Japan
| | - Y. Yamamoto
- Department of Plastic and Reconstructive Surgery; Graduate School of Medicine; University of Hokkaido at Sapporo, Kita-15 Nishi-7, Kita-Ku, Sapporo Hokkaido, 060-8638 Japan
| | - N. Yamazaki
- Department of Dermatologic Oncology; National Cancer Center Hospital; 5-1-1 Tsukiji, Chuo-ku Tokyo 104-0045 Japan
| |
Collapse
|
48
|
Tanaka R, Sasajima Y, Tsuda H, Namikawa K, Tsutsumida A, Otsuka F, Yamazaki N. Human epidermal growth factor receptor 2 protein overexpression and gene amplification in extramammary Paget disease. Br J Dermatol 2013; 168:1259-66. [DOI: 10.1111/bjd.12249] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
49
|
Yoshino K, Ishizuka Y, Sugihara N, Kariya N, Namura D, Noji I, Mitsuhashi K, Kimura H, Fukuda A, Kikukawa I, Hayashi T, Yamazaki N, Kimura M, Tsukiyama K, Yamamoto K, Fukuyama A, Hidaka D, Shinoda J, Mibu H, Shimakura Y, Saito A, Ikumi S, Umehara K, Kamei F, Fukuda H, Toake T, Takahashi Y, Miyata Y, Shioji S, Toyoda M, Hattori N, Nishihara H, Matsushima R, Nishibori M, Hokkedo O, Nojima M, Kimura T, Fujiseki M, Okudaira S, Tanabe K, Nakano M, Ito K, Kuroda M, Fukai K, Matsukubo T. Gender difference in tooth autotransplantation with complete root formation: a retrospective survey. J Oral Rehabil 2013; 40:368-74. [PMID: 23438017 DOI: 10.1111/joor.12038] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/30/2013] [Indexed: 11/28/2022]
Abstract
Gender-related risk factors in the survival of transplanted teeth with complete root formation have not yet been identified. The purpose of this study was to investigate gender differences in tooth autotransplantation at dental clinics. We asked participating dentists to provide information on transplantations they had undertaken from 1 January 1990 to 1931 December 2010. The data were screened to exclude patients who underwent more than one transplantation, smokers or those whose smoking habits were unknown, patients under 30 or who were 70 years old and over, cases where the transplanted teeth had incomplete root formation or multiple roots and those with fewer than 20 present teeth post-operation. We analysed 73 teeth of 73 males (mean age, 47.2 years) and 106 teeth of 106 females (mean age, 45.3 years) in this study. The cumulative survival rate and mean survival time were calculated using the Kaplan-Meier method. The cumulative survival rate for males was 88.3% at the 5-year mark, 64.8% at 10 years and 48.6% at 15 years; for females, it was 97.2% at the 5-year mark, 85.9% at 10 years and 85.9% at 15 years. A log-rank test indicated the difference between males and females to be significant (P = 0.011). There was also a significant difference in the main causes for the loss of transplanted teeth: males lost more transplanted teeth due to attachment loss than females (P < 0.05). These results indicate that males require more attention during the autotransplantation process, particularly at the stage of pre-operation evaluation and that of follow-up maintenance.
Collapse
Affiliation(s)
- K Yoshino
- Department of Epidemiology and Public Health, Tokyo Dental College, Chiba, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Yoshino K, Kariya N, Namura D, Noji I, Mitsuhashi K, Kimura H, Fukuda A, Kikukawa I, Hayashi T, Yamazaki N, Kimura M, Tsukiyama K, Yamamoto K, Fukuyama A, Hidaka D, Shinoda J, Mibu H, Shimakura Y, Saito A, Ikumi S, Umehara K, Kamei F, Fukuda H, Toake T, Takahashi Y, Miyata Y, Shioji S, Toyoda M, Hattori N, Nishihara H, Matsushima R, Nishibori M, Hokkedo O, Nojima M, Kimura T, Fujiseki M, Okudaira S, Tanabe K, Nakano M, Ito K, Kuroda M, Takiguchi T, Fukai K, Matsukubo T. Influence of age on tooth autotransplantation with complete root formation. J Oral Rehabil 2012; 40:112-8. [DOI: 10.1111/joor.12012] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/07/2012] [Indexed: 11/30/2022]
Affiliation(s)
- K. Yoshino
- Department of Epidemiology and Public Health; Tokyo Dental College; Chiba Japan
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - N. Kariya
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - D. Namura
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - I. Noji
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | | | - H. Kimura
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - A. Fukuda
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - I. Kikukawa
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - T. Hayashi
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - N. Yamazaki
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - M. Kimura
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | | | - K. Yamamoto
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - A. Fukuyama
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - D. Hidaka
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - J. Shinoda
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - H. Mibu
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | | | - A. Saito
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - S. Ikumi
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - K. Umehara
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - F. Kamei
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - H. Fukuda
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - T. Toake
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | | | - Y. Miyata
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - S. Shioji
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - M. Toyoda
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - N. Hattori
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | | | | | | | - O. Hokkedo
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - M. Nojima
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - T. Kimura
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - M. Fujiseki
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - S. Okudaira
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - K. Tanabe
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - M. Nakano
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - K. Ito
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - M. Kuroda
- Kyushikai, Kuroda Dental Clinic; Tokyo Japan
| | - T. Takiguchi
- Department of Health Informatics; Niigata University of Health and Welfare; Niigata Japan
| | - K. Fukai
- Fukai Institute of Health Science; Saitama Japan
| | - T. Matsukubo
- Department of Epidemiology and Public Health; Tokyo Dental College; Chiba Japan
| |
Collapse
|